The FDA approved Eli Lilly’s once-daily oral GLP-1 weight-loss pill Foundayo (orforglipron), setting up head-to-head commercial pressure against Novo Nordisk’s recently launched oral Wegovy pill. The approval arrives through the agency’s Commissioner’s National Priority Review pilot, and Lilly said it plans to begin distribution immediately after launch timing. Lilly’s label covers adults with obesity or overweight with weight-related conditions, in combination with diet and increased physical activity. In clinical testing, orforglipron achieved about 11% average weight loss at the highest dose in people with obesity without diabetes and about 10% in those with obesity and diabetes. For Novo, the approval compounds the competitive challenge created by its own oral GLP-1 push. Both products have shown comparable weight reduction in their respective trials, but they differ in dosing logistics and patient access routes—factors that are increasingly decisive for payer coverage and real-world uptake. Separately, Ambrosia Biosciences also secured $100 million in oversubscribed Series B funding to advance its own oral small-molecule GLP-1 candidate into clinical development, underscoring continued investor appetite for non-injectable options as the market approaches scale.